RxDoctor Payments Data

Charles Thompson, MD

Interventional Cardiology · Zachary, LANPI 1528260072

Payments from drug & device makers

What this record shows

This record is dominated by other: $59,250 of the $73,510 with a category attached, or 80.6%. Angiodynamics, Inc. accounts for 82.6% of it on its own, with 46 other manufacturers making up the rest. 2025 is the largest year on record at $33,060, more than ten times the $2,550 reported in 2019.

$73,510in general payments, 2019–2025

Across 513 payments — averaging $143.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$61K
  • Philips North America LLC$2K
  • Shockwave Medical, Inc$1K
  • Novartis$950
  • Biotronik Inc.$851
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$843
  • plus $7K from 41 others
$57,466in research payments, 2019–2025

Across 25 payments — averaging $2298.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$27K
  • Siemens Medical Solutions USA, Inc.$17K
  • AstraZeneca$8K
  • Novartis$6K

What the payments were for

  • Consulting fees$7501%
  • Travel & lodging$9111%
  • Food & beverage$12,53917%
  • Education$600%
  • Other$59,25081%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,510 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$317,433
Medicare patients
1,046
Services billed
5,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban739$625,208
XareltoRivaroxaban301$251,280
EntrestoSacubitril/Valsartan179$180,919
FarxigaDapagliflozin Propanediol166$120,153
Repatha SureclickEvolocumab115$105,759
BrilintaTicagrelor49$27,107
JardianceEmpagliflozin21$24,383
CorlanorIvabradine Hcl16$16,770
NexlizetBempedoic Acid/Ezetimibe34$15,490
Ranolazine ErRanolazine196$13,759
Atorvastatin Calcium1,503$13,436
Nifedipine ErNifedipine385$7,815
Potassium Chloride593$7,792
Rosuvastatin Calcium589$7,681
Metoprolol Tartrate1,381$7,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$372$625,208739 claims
Johnson & JohnsonXarelto$580$251,280301 claims
NovartisEntresto$950$180,919179 claims
AstraZenecaFarxiga, Brilinta$110$147,260215 claims
Boehringer IngelheimJardiance$88$24,38321 claims
AmgenCorlanor$385$16,77016 claims
Esperion Therapeutics, Inc.Nexlizet$125$15,49034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Zachary

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →